

ASCEND - A randomized trial of aspirin versus placebo for primary cardiovascular prevention in 15,480 people with diabetes

Purpose: Study of the role of aspirin for primary heart attack and stroke prevention in healthy people with diabetes.

Trial Design: N=15,480. Phase 4; randomized to 100mg daily aspirin versus placebo. 7.4 years follow-up.

Primary Endpoints:

EFFICACY: *combined* myocardial infarction, stroke or transient ischaemic attack, or vascular death, (does not include confirmed cerebral haemorrhage).

SAFETY: First major bleeding

	aspirin	placebo	P value
Combined adverse events	8.5%	9.6%	0.01
Major bleeding	4.1%	3.2%	0.003
GI cancer	2%	2%	
All cancers	11.6%	11.5%	

Results: The use of low-dose aspirin for in these diabetic patients reduced major adverse vascular events but caused more major bleeding.

